CN101500995A - 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物 - Google Patents

用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物 Download PDF

Info

Publication number
CN101500995A
CN101500995A CNA2007800155890A CN200780015589A CN101500995A CN 101500995 A CN101500995 A CN 101500995A CN A2007800155890 A CNA2007800155890 A CN A2007800155890A CN 200780015589 A CN200780015589 A CN 200780015589A CN 101500995 A CN101500995 A CN 101500995A
Authority
CN
China
Prior art keywords
alkyl
group
alkoxy
haloalkyl
alkylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800155890A
Other languages
English (en)
Chinese (zh)
Inventor
吉尔·海姆斯凯克
基思·D·巴尔内思
约翰·M·麦考尔
格雷厄姆·约翰逊
大卫·费尔法克斯
马修斯·罗伯特·约翰逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curia Global Inc
US Department of Health and Human Services
Original Assignee
Science Applications International Corp SAIC
Albany Molecular Research Inc
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Science Applications International Corp SAIC, Albany Molecular Research Inc, US Department of Health and Human Services filed Critical Science Applications International Corp SAIC
Publication of CN101500995A publication Critical patent/CN101500995A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2007800155890A 2006-03-17 2007-03-16 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物 Pending CN101500995A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78329206P 2006-03-17 2006-03-17
US60/783,292 2006-03-17

Publications (1)

Publication Number Publication Date
CN101500995A true CN101500995A (zh) 2009-08-05

Family

ID=38477008

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800155890A Pending CN101500995A (zh) 2006-03-17 2007-03-16 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物

Country Status (10)

Country Link
US (2) US8110681B2 (enExample)
EP (1) EP2027088A2 (enExample)
JP (2) JP2009530306A (enExample)
CN (1) CN101500995A (enExample)
AU (1) AU2007227398C1 (enExample)
BR (1) BRPI0708801A2 (enExample)
CA (1) CA2645426A1 (enExample)
IL (1) IL194153A0 (enExample)
WO (1) WO2007109211A2 (enExample)
ZA (1) ZA200807936B (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762548A (zh) * 2009-12-22 2012-10-31 沃泰克斯药物股份有限公司 磷脂酰肌醇3-激酶的异吲哚啉酮抑制剂
WO2013062028A1 (ja) * 2011-10-25 2013-05-02 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
CN105801556A (zh) * 2014-12-31 2016-07-27 上海药谷药业有限公司 一种2,3-二氢-1,4-苯并二烷-6-羧酸化合物的制备方法
CN107074817A (zh) * 2014-08-29 2017-08-18 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
CN108299314A (zh) * 2012-02-10 2018-07-20 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
CN108697709A (zh) * 2015-12-10 2018-10-23 Ptc医疗公司 用于治疗亨廷顿病的方法
CN110121343A (zh) * 2016-09-12 2019-08-13 数值有限公司 用作gpr120调节剂的双环化合物
CN115141097A (zh) * 2022-06-27 2022-10-04 重庆医药高等专科学校 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的生产线系统
CN115304472A (zh) * 2022-06-27 2022-11-08 重庆医药高等专科学校 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的合成方法
US11548886B2 (en) 2016-09-12 2023-01-10 Valo Health, Inc. Monocyclic compounds useful as GPR120 modulators
CN117740969A (zh) * 2023-11-30 2024-03-22 杭州志呈科技有限公司 一种吲哚布芬杂质检测方法及其应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100267712A1 (en) * 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009052350A1 (en) * 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Amine linked modulators of y-secretase
JP5632612B2 (ja) * 2007-12-05 2014-11-26 あすか製薬株式会社 ラクタム化合物又はその塩及びｐｐａｒ活性化剤
JP5484316B2 (ja) * 2008-02-28 2014-05-07 財団法人乙卯研究所 芳香族アミド誘導体
US20210130285A1 (en) 2008-03-19 2021-05-06 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
US10793515B2 (en) 2008-03-19 2020-10-06 Aurimmed Pharma, Inc. Compounds advantageous in the treatment of central nervous system diseases and disorders
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
GB0909671D0 (en) 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
JP6097998B2 (ja) * 2010-12-16 2017-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のビアリールアミドインヒビター
NO3175985T3 (enExample) 2011-07-01 2018-04-28
AU2013203252B2 (en) 2012-01-27 2015-08-20 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9212209B2 (en) * 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
EP2921480B1 (en) * 2012-11-19 2017-10-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
BR112015015075A2 (pt) * 2012-12-24 2019-01-15 Univ Ramot agentes para tratar doenças genéticas resultantes de mutações sem sentido e métodos para identificar as mesmas.
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
JP6846363B2 (ja) * 2015-07-14 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ２−フェニル−６−イミダゾリル−ピリジン−４−カルボキサミド誘導体及びそのｅａａｔ３阻害剤としての使用
WO2017066103A1 (en) * 2015-10-16 2017-04-20 Aurimmed Pharma, Inc. Novel compounds advantageous in the treatment of central nervous system diseases and disorders
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
JP7376471B2 (ja) 2017-06-05 2023-11-08 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероарильные соединения для лечения болезни гентингтона
KR20220035937A (ko) 2019-07-25 2022-03-22 노파르티스 아게 조절 가능한 발현 시스템
KR102186761B1 (ko) * 2020-06-03 2020-12-04 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물을 포함하는 파킨슨병 예방 또는 치료용 약학적 조성물
WO2022115301A1 (en) * 2020-11-24 2022-06-02 Merck Sharp & Dohme Corp. Modified isoindolinones as glucosylceramide synthase inhibitors
KR102883783B1 (ko) * 2022-12-15 2025-11-12 옙바이오 주식회사 2-(4-(1-하이드록시프로판-2-일)페닐)이소인돌린-1-온 화합물 제조방법
KR102597093B1 (ko) * 2023-06-07 2023-11-03 옙바이오 주식회사 줄기세포 노화 억제 신규 화합물 및 이의 약학적 용도

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641040A (en) * 1968-03-27 1972-02-08 Ciba Geigy Corp Tertiary amino phenyl acetic acids
US4126691A (en) 1968-03-27 1978-11-21 Ciba-Geigy Corporation Tertiary aminoacids
DE2034240C2 (de) 1968-03-27 1982-12-02 CIBA-GEIGY AG, 4002 Basel Isoindolinderivate, Verfahren zur Herstellung dieser Verbindungen und deren Verwendung
US3542806A (en) 1968-03-29 1970-11-24 Robins Co Inc A H 2-(1-substituted-3-pyrrolidinyl)-isoindolines
DE2046992A1 (en) * 1970-09-24 1972-03-30 Merck Patent Gmbh, 6100 Darmstadt Isoindolinophenyl-alkanoic acid esters and salts - - antiphlogistic, antipyretic and analgesic agents
DE2154525A1 (de) * 1970-11-05 1972-06-15 Carlo Erba S.P.A., Mailand (Italien) Isoindolinderivate und Verfahren zu ihrer Herstellung
FI53702C (fi) * 1971-11-22 1978-07-10 Erba Carlo Spa Foerfarande foer framstaellning av isoindolinderivat
US3890346A (en) * 1972-03-22 1975-06-17 Monsanto Co Process for the preparation of N-arylphthalimidines
GB1413173A (en) * 1972-07-07 1975-11-12 Bp Chem Int Ltd Polymerisation process
US3997669A (en) 1972-12-26 1976-12-14 Ciba-Geigy Corporation Tertiary aminoacids
JPS5233667A (en) * 1975-09-11 1977-03-14 Fuji Kagaku Kogyo Kk Process for preparation of hydrogenated 1-oxo-isoindoline derivatives
IT1113035B (it) * 1979-03-06 1986-01-20 Erba Farmitalia Esteri c alla 3 - c alla 4 aclhilici di 1-oxo-2- aperta par.graffa p aperta par. quadrata (alfa-metil) -carbossimetil chiusa par. quadrata - fenil chiusa par. graffa- isoindolina
JPS5644686A (en) 1979-09-21 1981-04-23 Hodogaya Chem Co Ltd Pressure-sensitive reproducing paper
JPS5645955A (en) 1979-09-21 1981-04-25 Hodogaya Chem Co Ltd 6-(2,3-dihydroisoindol-2-yl)fluoran compound
JPS5750960A (en) * 1980-09-10 1982-03-25 Hisamitsu Pharmaceut Co Inc Preparation of novel 4- 1-oxo-2-isoindolinyl acetophenone
JPS5845088A (ja) 1981-09-09 1983-03-16 Sumitomo Chem Co Ltd 記録紙
JPH0262875A (ja) 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
JPH03181478A (ja) 1989-12-08 1991-08-07 Banyu Pharmaceut Co Ltd ピリドンカルボン酸誘導体
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5567718A (en) 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
DE69841267D1 (de) * 1997-03-10 2009-12-10 Univ Loma Linda Med Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit
ATE277035T1 (de) 1998-12-23 2004-10-15 Schering Corp Substituierte oxime und hydrazone als neurokinin antagonisten
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
JP2004515494A (ja) 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ 治療剤
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
CA2493458A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
US7691847B2 (en) 2002-10-17 2010-04-06 The Trustees Of The University Of Pennsylvania Method of treating neurological diseases and disorders
DK1566378T3 (da) 2002-11-26 2012-11-12 Maruishi Pharma Isoindolinderivat
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
WO2006050451A2 (en) 2004-11-02 2006-05-11 Whitehead Institute For Biomedical Research Methods and compositions to treat motor neuron disease
CA2640274A1 (en) 2006-02-03 2007-08-09 Glaxo Group Limited Benzoisoindole derivatives for the treatment of pain
JP5190062B2 (ja) 2006-10-12 2013-04-24 ノバルティス アーゲー Ｉａｐ阻害剤としてのピロリジン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACS: "RN 865701-39-9等", 《STN REGISTRY》 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102762548B (zh) * 2009-12-22 2014-11-26 沃泰克斯药物股份有限公司 磷脂酰肌醇3-激酶的异吲哚啉酮抑制剂
CN102762548A (zh) * 2009-12-22 2012-10-31 沃泰克斯药物股份有限公司 磷脂酰肌醇3-激酶的异吲哚啉酮抑制剂
WO2013062028A1 (ja) * 2011-10-25 2013-05-02 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
CN108299314A (zh) * 2012-02-10 2018-07-20 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
CN107074817B (zh) * 2014-08-29 2023-12-15 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
US11071793B2 (en) 2014-08-29 2021-07-27 Chdi Foundation, Inc. Probes for imaging huntingtin protein
US12036291B2 (en) 2014-08-29 2024-07-16 Chdi Foundation, Inc. Probes for imaging huntingtin protein
CN107074817A (zh) * 2014-08-29 2017-08-18 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
CN105801556A (zh) * 2014-12-31 2016-07-27 上海药谷药业有限公司 一种2,3-二氢-1,4-苯并二烷-6-羧酸化合物的制备方法
CN108697709A (zh) * 2015-12-10 2018-10-23 Ptc医疗公司 用于治疗亨廷顿病的方法
CN113717154B (zh) * 2015-12-10 2024-11-15 Ptc医疗公司 用于治疗亨廷顿病的方法
CN110946865A (zh) * 2015-12-10 2020-04-03 Ptc医疗公司 用于治疗亨廷顿病的方法
CN113717154A (zh) * 2015-12-10 2021-11-30 Ptc医疗公司 用于治疗亨廷顿病的方法
CN110946865B (zh) * 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
US11548886B2 (en) 2016-09-12 2023-01-10 Valo Health, Inc. Monocyclic compounds useful as GPR120 modulators
CN110121343B (zh) * 2016-09-12 2023-11-03 整体健康 用作gpr120调节剂的双环化合物
US11919891B2 (en) 2016-09-12 2024-03-05 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
US12116362B2 (en) 2016-09-12 2024-10-15 Valo Health, Inc. Monocyclic compounds useful as GPR120 modulators
CN110121343A (zh) * 2016-09-12 2019-08-13 数值有限公司 用作gpr120调节剂的双环化合物
CN115304472A (zh) * 2022-06-27 2022-11-08 重庆医药高等专科学校 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的合成方法
CN115141097A (zh) * 2022-06-27 2022-10-04 重庆医药高等专科学校 一种弗雷拉纳中间体4-溴-2-甲基苯甲酸的生产线系统
CN117740969A (zh) * 2023-11-30 2024-03-22 杭州志呈科技有限公司 一种吲哚布芬杂质检测方法及其应用
CN117740969B (zh) * 2023-11-30 2025-01-10 杭州志呈科技有限公司 一种吲哚布芬杂质检测方法及其应用

Also Published As

Publication number Publication date
EP2027088A2 (en) 2009-02-25
AU2007227398A8 (en) 2008-11-27
WO2007109211A8 (en) 2009-02-12
US20120083495A1 (en) 2012-04-05
WO2007109211A3 (en) 2007-12-13
JP2013116901A (ja) 2013-06-13
US20090312323A1 (en) 2009-12-17
AU2007227398C1 (en) 2013-05-30
CA2645426A1 (en) 2007-09-27
IL194153A0 (en) 2009-08-03
US8110681B2 (en) 2012-02-07
BRPI0708801A2 (pt) 2011-06-14
AU2007227398A1 (en) 2007-09-27
JP2009530306A (ja) 2009-08-27
AU2007227398B2 (en) 2012-09-27
ZA200807936B (en) 2009-12-30
WO2007109211A2 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
CN101500995A (zh) 用于治疗脊髓型肌萎缩和其它用途的1-氧代-异吲哚啉化合物
EP2215074B1 (en) Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
JP7653166B2 (ja) ＣＣＲ８阻害剤を使用してＴｒｅｇｓを標的とする方法および組成物
CN110621317B (zh) 组蛋白去乙酰化酶（hdacs）抑制剂
JP2006520796A (ja) ヒストンデアセチラーゼインヒビター
CN101505747A (zh) 作为细胞增殖抑制剂的吡嗪酮
JP5009151B2 (ja) Ｂｃｒｐ／ａｂｃｇ２阻害剤
HUT77740A (hu) 2,5-Dioxo-piperazin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
US10227306B2 (en) Compounds for inhibiting c-myc/max/DNA complex formation
EP2097374B1 (fr) Derives de 5-alkyloxy-indolin-2-one, leur preparation et leurs applications en therapeutique comme ligands selectives des recepteurs v2 de la vasopressine
KR101086246B1 (ko) 치환된 스피로벤즈아제핀
CN109715607B (zh) 抑制c-myc/max/dna复合物形成的化合物
WO2012142459A1 (en) Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
CN116178700B (zh) Peg化吲哚菁染料偶联紫杉醇前药型化合物及其制备和应用
AU2005226741A1 (en) Acrylonitrile derivatives for inflammation and immune-related uses
WO2018163204A1 (en) Cathepsin-d and angiogenesis inhibitors and compositions thereof for treating breast cancer
Aliwi Synthesis of Some New 2-thioxoimidazolidin-4-one Derivatives (part I)
JP2000001486A (ja) グアニジン誘導体
HK1120258B (en) Bcrp/abcg2 inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ALBANY MOLECULAR RESEARCH INC.

Free format text: FORMER OWNER: ALBANY MOLECULAR RESEARCH INC. SCIENCE APPLICATIONS INTERNATIONAL CORPORATION

Effective date: 20130718

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130718

Address after: American Maryland

Applicant after: Department of Health and Human Services of United States

Applicant after: Albany Molecular Research Co Ltd

Address before: American Maryland

Applicant before: Department of Health and Human Services of United States

Applicant before: Albany Molecular Research Co Ltd

Applicant before: Science Applic Int Corp.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090805